-

New, Innovative GC and GC-MS Product Portfolio Enables Greater Uptime and Efficiency

Updated GC and GC-MS portfolio from Thermo Fisher Scientific designed to deliver enhanced customer experience, easy adoption and simplified operations

AUSTIN, Texas--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, enables analytical testing laboratories across a variety of sectors, including food, environmental, industrial and pharma to now meet their ever-increasing efficiency and productivity needs with a collection of new gas chromatography (GC) and GC-mass spectrometry (GC-MS) instruments offering innovative hardware and software updates.

The GC/GC-MS instrument portfolio, including the new Thermo Scientific TRACE 1600 Series Gas Chromatograph, Thermo Scientific AI/AS 1610 Liquid Autosampler, Thermo Scientific ISQ 7610 Single Quadrupole GC-MS and Thermo Scientific TSQ 9610 Triple Quadrupole GC-MS/MS, now features technological advances that enhance usability and productivity.

“We designed this portfolio of GC/GC-MS instruments with the customer experience in mind, gathering feedback from customers throughout the development process,” said Fabrizio Moltoni, vice president and general manager, applied analytical technologies, chromatography and mass spectrometry, Thermo Fisher Scientific. “Our portfolio is continuously evolving to help our customers overcome new challenges, simplify operations, allow for easy compliance and reduce waste. These new instruments bring these efforts to fruition by helping laboratories avoid unplanned downtime and easy adoption with intuitive technology.”

Katie Banaszewski, director of quality, Now Foods, said, “One of the things we like about working with Thermo Fisher Scientific is they listen to customer feedback and introduce new solutions based on that feedback. We tested the TSQ 9610 Triple Quadrupole GC-MS/MS with the Trace 1610 GC and AI/AS autosampler. This is a very robust, high-sensitivity system that is easy to operate and maintain, making it great for high throughput laboratories. We consider Thermo Fisher’s instruments some of the most advanced and robust systems available, but more importantly, they offer superior service, technical expertise and support.”

Features of the new Thermo Scientific GC/GC-MS instruments include:

  • Unique GC modularity and NeverVent technologies that enable increased instrument uptime by accelerating maintenance operations through user-exchangeable injectors and detectors modules, and the ability to remove MS ion source, filaments and analytical column without breaking the vacuum.
  • Wider high-resolution multi-function touch screen, tool-free column connection
  • Illuminated GC oven and autosampler syringe compartment
  • Support from how-to videos directly on the GC touch screen for quick familiarization and adoption
  • Consistent sensitivity and extended linear dynamic range of the new MS detector that enable methods consolidation for maximized sample throughput—a critical need for analytical laboratories performing a high volume of tests.

To learn more about the new products in the GC and GC-MS portfolio, register to attend Thermo Fisher’s Innovation Summit: “Stay Ahead with new GC and GCMS Technology” on March 8, 2022.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
Thermo Fisher Scientific meets lab's efficiency and productivity needs with a collection of new GC and GC-MS instruments.
Release Versions

Contacts

Media:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom